Research graph
References from Integrating Static and Dynamic Models to Predict Cannabidiol‐Mediated Metabolic Drug–Drug Interactions. Local targets link to admitted publications; unresolved targets remain external evidence.
Phytochemistry of Cannabis sativa L
2017 · External reference
A marijuana‐drug interaction primer: precipitants, pharmacology, and pharmacokinetics
10.1016/j.pharmthera.2019.05.001 · 2019 · External reference
Unresolved reference
2026 · External reference
A brief background on cannabis: from plant to medical indications
10.5740/jaoacint.18-0208 · 2019 · External reference
Comprehensive predictions of cytochrome P450 (P450)‐mediated in vivo cannabinoid‐drug interactions based on reversible and time‐dependent P450 inhibition in human liver Microsomes
10.1124/dmd.121.000734 · 2022 · External reference
Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis‐drug interactions
10.1124/dmd.121.000442 · 2021 · External reference
CBD and THC in special populations: pharmacokinetics and drug–drug interactions
10.3390/pharmaceutics16040484 · 2024 · External reference
Unresolved reference
External reference
Physiologically based pharmacokinetic modeling of Cannabidiol, Delta‐9‐tetrahydrocannabinol, and their metabolites in healthy adults after administration by multiple routes
10.1111/cts.70119 · 2025 · External reference
Using a PBPK model incorporating lymphatic absorption to predict food effect, multiple dosing, and hepatic impairment of Cannabidiol
10.1111/cts.70401 · 2025 · External reference
Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling
10.1002/psp4.12908 · 2023 · External reference
A physiologically‐based pharmacokinetic model for Cannabidiol in healthy adults, Hepatically‐impaired adults, and children
10.1124/dmd.122.001128 · 2023 · External reference
Prediction of carboxylesterase 1‐mediated in vivo drug interaction between methylphenidate and cannabinoids using static and physiologically based pharmacokinetic models
10.1124/dmd.121.000823 · 2022 · External reference
Evaluation of cytochrome P450‐ mediated Cannabinoid–drug interactions in healthy adult participants
10.1002/cpt.2973 · 2023 · External reference
A phase 1, open‐label, pharmacokinetic trial to investigate possible drug‐drug interactions between Clobazam, Stiripentol, or valproate and Cannabidiol in healthy subjects
10.1002/cpdd.665 · 2019 · External reference
Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450
10.1124/dmd.120.000073 · 2020 · External reference
Unresolved reference
External reference
Prediction of pharmacokinetic alterations caused by drug‐drug interactions: metabolic interaction in the liver
10.1016/s0031-6997(24)01372-3 · 1998 · External reference
Single‐dose kinetics of deuterium‐labelled cannabidiol in man after smoking and intravenous administration
10.1002/bms.1200130206 · 1986 · External reference
Relative performance of volume of distribution prediction methods for lipophilic drugs with uncertainty in LogP value
10.1007/s11095-024-03703-4 · 2024 · External reference
A phase I, randomized, double‐blind, placebo‐controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified Cannabidiol in healthy subjects
10.1007/s40263-018-0578-5 · 2018 · External reference
A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
10.1111/epi.16419 · 2020 · External reference
A phase I, open‐label, parallel‐group, single‐dose trial of the pharmacokinetics, safety, and tolerability of Cannabidiol in subjects with mild to severe renal impairment
10.1007/s40262-019-00841-6 · 2020 · External reference
A phase 1, open‐label, parallel‐group, single‐dose trial of the pharmacokinetics and safety of Cannabidiol (CBD) in subjects with mild to severe hepatic impairment
10.1002/jcph.1412 · 2019 · External reference
Cytochrome P450–catalyzed metabolism of Cannabidiol to the active metabolite 7‐Hydroxy‐Cannabidiol
10.1124/dmd.120.000350 · 2021 · External reference
Randomized, dose‐ranging safety trial of cannabidiol in Dravet syndrome
10.1212/wnl.0000000000005254 · 2018 · External reference
Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations
10.1124/dmd.114.058099 · 2014 · External reference
Inhibition of UDP‐glucuronosyltransferase enzymes by major cannabinoids and their metabolites
10.1124/dmd.121.000530 · 2021 · External reference
Unresolved reference
External reference
A phase 1 open‐label, fixed‐sequence pharmacokinetic drug interaction trial to investigate the effect of Cannabidiol on the CYP1A2 probe caffeine in healthy subjects
10.1002/cpdd.950 · 2021 · External reference
Physiologically based pharmacokinetic modeling of Clobazam and Stiripentol Co‐therapy in Dravet syndrome
10.3390/jpm15110549 · 2025 · External reference
A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: an evaluation of CYP2C19 activity
10.1002/prp2.946 · 2022 · External reference
Physiologically based pharmacokinetic approach can successfully predict pharmacokinetics of citalopram in different patient populations
10.1002/jcph.1541 · 2020 · External reference
Impact of CYP2C19 phenotype on Escitalopram response in geriatrics: based on physiologically‐based pharmacokinetic modeling and clinical observation
10.1002/cpt.3537 · 2025 · External reference
Prediction of CYP‐mediated DDIs involving inhibition: approaches to address the requirements for system qualification of the Simcyp simulator
10.1002/psp4.12794 · 2022 · External reference
The quantitative prediction of CYP‐mediated drug interaction by physiologically based pharmacokinetic modeling
10.1007/s11095-008-9607-2 · 2008 · External reference
Static and dynamic projections of drug‐drug interactions caused by cytochrome P450 3A time‐dependent inhibitors measured in human liver Microsomes and hepatocytes
10.1124/dmd.121.000497 · 2021 · External reference
Drug interaction PBPK modeling: review of the literature exposes the need for increased verification of model inputs and outputs as part of credibility assessment
10.1111/cts.70299 · 2025 · External reference
Prediction of drug‐drug interactions arising from CYP3A induction using a physiologically based dynamic model
10.1124/dmd.115.066845 · 2016 · External reference
Cannabidiol and Δ9‐tetrahydrocannabinol induce drug‐metabolizing enzymes, but not transporters, in human hepatocytes: implications for predicting complex cannabinoid–drug interactions
10.1016/j.dmd.2025.100037 · 2025 · External reference
Unresolved reference
External reference
Comparison of different approaches to predict metabolic drug‐drug interactions
2007 · External reference
Static versus dynamic model predictions of competitive inhibitory metabolic drug–drug interactions via cytochromes P450: one step forward and two steps backwards
10.1007/s40262-024-01457-1 · 2025 · External reference
Citalopram and Cannabidiol: in vitro and in vivo evidence of pharmacokinetic interactions relevant to the treatment of anxiety disorders in young people
10.1097/jcp.0000000000001427 · 2021 · External reference
Predicting in vivo cannabinoid‐drug interactions mediated via inhibition of UDP‐glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations
10.1016/j.dmd.2025.100096 · 2025 · External reference
A phase I trial of the pharmacokinetic interaction between Cannabidiol and tacrolimus
10.1002/cpt.3504 · 2025 · External reference
Pharmacokinetic drug‐drug interaction with Coadministration of Cannabidiol and Everolimus in a phase 1 healthy volunteer trial
10.1002/cpdd.1262 · 2023 · External reference
Inhibition of tacrolimus metabolism by Cannabidiol and its metabolites in vitro
10.1111/cts.70152 · 2025 · External reference
